Immune cell boost for leukemia relapse after stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether giving extra immune cells (called DLI) before or after a stem cell transplant can help prevent or treat leukemia relapse. These cells come from the same family member who donated your transplant, and the study also asks the donor to do some exercise sessions beforehand.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are aged 0 to 65 years.
- You have a blood cancer such as acute leukemia, myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), or non-Hodgkin's lymphoma (NHL).
- You have had or plan to have a stem cell transplant from a matched sibling or a half-matched family donor.
- Your donor (matched or half-matched family member) is between 12 and 50 years old, weighs over 30 kg, and is healthy enough to donate.
- You are not currently being treated for severe graft-versus-host disease (GVHD).
- Your major organs (like heart, lungs, liver, and kidneys) are functioning well enough, and you are generally in stable condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This study tests whether giving donor immune cells earlier or later after a stem cell transplant helps prevent relapse in people with tough-to-treat leukemia or MDS. Participants must be in remission one month after transplant.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
Hear when a new Acute Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.